Published in J Vasc Surg on December 01, 2009
Severe venous neointimal hyperplasia prior to dialysis access surgery. Nephrol Dial Transplant (2011) 1.54
Stromal endothelial cells directly influence cancer progression. Sci Transl Med (2011) 1.46
Ultrasound-guided percutaneous delivery of tissue-engineered endothelial cells to the adventitia of stented arteries controls the response to vascular injury in a porcine model. J Vasc Surg (2012) 1.42
Vascular access in haemodialysis: strengthening the Achilles' heel. Nat Rev Nephrol (2013) 1.09
Novel paradigms for dialysis vascular access: downstream vascular biology--is there a final common pathway? Clin J Am Soc Nephrol (2013) 0.89
Therapeutic strategies to combat neointimal hyperplasia in vascular grafts. Expert Rev Cardiovasc Ther (2012) 0.87
The effect of substrate modulus on the growth and function of matrix-embedded endothelial cells. Biomaterials (2012) 0.85
The role of scaffold microarchitecture in engineering endothelial cell immunomodulation. Biomaterials (2012) 0.84
Novel paradigms for dialysis vascular access: Introduction. Clin J Am Soc Nephrol (2013) 0.83
Novel therapies for hemodialysis vascular access dysfunction: myth or reality? Clin J Am Soc Nephrol (2013) 0.82
Taking tissue engineering to heart. Nat Med (2011) 0.81
Matrix-embedded endothelial cells are protected from the uremic milieu. Nephrol Dial Transplant (2011) 0.80
Periadventitial drug delivery for the prevention of intimal hyperplasia following open surgery. J Control Release (2016) 0.77
Cell matrix contact modifies endothelial major histocompatibility complex class II expression in high-glucose environment. Am J Physiol Heart Circ Physiol (2013) 0.75
Biomaterial-Based Approaches to Address Vein Graft and Hemodialysis Access Failures. Macromol Rapid Commun (2016) 0.75
Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med (2006) 5.88
Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff (Millwood) (2006) 4.33
Specialty of ambulatory care physicians and mortality among elderly patients after myocardial infarction. N Engl J Med (2002) 4.05
Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A (2008) 2.73
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68
How deceased donor transplantation is impacting a decline in commercial transplantation-the Tamil Nadu experience. Transplantation (2012) 2.14
Readily available tissue-engineered vascular grafts. Sci Transl Med (2011) 2.13
Decellularized tissue-engineered blood vessel as an arterial conduit. Proc Natl Acad Sci U S A (2011) 1.94
A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. Ann Surg (2010) 1.83
Decreased cumulative access survival in arteriovenous fistulas requiring interventions to promote maturation. Clin J Am Soc Nephrol (2010) 1.75
Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation (2008) 1.66
Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes (2008) 1.63
Anatomic configuration affects the flow rate and diameter of porcine arteriovenous fistulae. Kidney Int (2012) 1.58
Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J Virol (2006) 1.58
Severe venous neointimal hyperplasia prior to dialysis access surgery. Nephrol Dial Transplant (2011) 1.54
Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis. Adv Chronic Kidney Dis (2009) 1.52
Human arteries engineered in vitro. EMBO Rep (2003) 1.51
Use of aspirin associates with longer primary patency of hemodialysis grafts. J Am Soc Nephrol (2011) 1.49
Photoinstability of S-nitrosothiols during sampling of whole blood: a likely source of error and variability in S-nitrosothiol measurements. Clin Chem (2008) 1.48
Analysis of infection risk following covered stent exclusion of pseudoaneurysms in prosthetic arteriovenous hemodialysis access grafts. J Vasc Interv Radiol (2011) 1.43
Multidisciplinary approach to the challenge of hemostasis. Anesth Analg (2009) 1.37
Early arteriovenous fistula failure: a logical proposal for when and how to intervene. Clin J Am Soc Nephrol (2005) 1.32
Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial. Clin Trials (2005) 1.31
Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation (2010) 1.25
Venous stenosis in a pig arteriovenous fistula model--anatomy, mechanisms and cellular phenotypes. Nephrol Dial Transplant (2007) 1.22
Early biomechanical changes in lower extremity vein grafts--distinct temporal phases of remodeling and wall stiffness. J Vasc Surg (2006) 1.19
West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and death. Transplantation (2004) 1.18
Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation (2008) 1.16
Aggressive venous neointimal hyperplasia in a pig model of arteriovenous graft stenosis. Kidney Int (2002) 1.12
The combination of donor and recipient age is critical in determining host immunoresponsiveness and renal transplant outcome. Ann Surg (2010) 1.12
A link between PDL1 and T regulatory cells in fetomaternal tolerance. J Immunol (2007) 1.12
The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J Immunol (2011) 1.10
Protease-activated receptor-2 signaling triggers dendritic cell development. Am J Pathol (2003) 1.09
Vascular access in haemodialysis: strengthening the Achilles' heel. Nat Rev Nephrol (2013) 1.09
Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia. J Vasc Surg (2011) 1.08
The biocompatibility of titanium cardiovascular devices seeded with autologous blood-derived endothelial progenitor cells: EPC-seeded antithrombotic Ti implants. Biomaterials (2010) 1.08
Coagulopathy and inflammation in neonatal heart surgery: mechanisms and strategies. Ann Thorac Surg (2006) 1.06
The coagulopathy of trauma versus disseminated intravascular coagulation. J Trauma (2006) 1.05
Adventitial endothelial implants reduce matrix metalloproteinase-2 expression and increase luminal diameter in porcine arteriovenous grafts. J Vasc Surg (2007) 1.04
Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice. Clin Immunol (2007) 1.04
TIM-3 regulates innate immune cells to induce fetomaternal tolerance. J Immunol (2012) 1.04
Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation (2002) 1.03
Matrix embedding alters the immune response against endothelial cells in vitro and in vivo. Circulation (2005) 1.02
Clinical epidemiology of arteriovenous fistula in 2007. J Nephrol (2007) 1.02
Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg (2003) 1.02
Acute in-vivo evaluation of bleeding with Gelfoam plus saline and Gelfoam plus human thrombin using a liver square lesion model in swine. J Thromb Thrombolysis (2008) 1.02
Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids. Clin Transplant (2008) 1.01
Perivascular paclitaxel wraps block arteriovenous graft stenosis in a pig model. Nephrol Dial Transplant (2006) 1.00
Fostering innovation, advancing patient safety: the kidney health initiative. Clin J Am Soc Nephrol (2013) 1.00
Early adaptation of human lower extremity vein grafts: wall stiffness changes accompany geometric remodeling. J Vasc Surg (2004) 0.99
A multi-center, dose-escalation study of human type I pancreatic elastase (PRT-201) administered after arteriovenous fistula creation. J Vasc Access (2012) 0.98
Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. Transplantation (2011) 0.98
Recent clinical and investigational applications of fibrin sealant in selected surgical specialties. J Am Coll Surg (2006) 0.98
Selection and plan switching behavior. Inquiry (2006) 0.97
Congenital jugular vein phlebectasia: a case report and review of the literature. Ann Vasc Surg (2008) 0.97
Preoperative risk factors for carotid endarterectomy: defining the patient at high risk. J Vasc Surg (2003) 0.96
Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial. Clin Trials (2005) 0.96
Review of the biology of bleeding and clotting in the surgical patient. Vascular (2008) 0.95
Hemodynamic wall shear stress profiles influence the magnitude and pattern of stenosis in a pig AV fistula. Kidney Int (2008) 0.95
Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression. Am J Transplant (2005) 0.94
Fibrin sealant improves hemostasis in peripheral vascular surgery: a randomized prospective trial. Ann Surg (2003) 0.94
Preexisting venous calcification prior to dialysis vascular access surgery. Semin Dial (2012) 0.94
Pathophysiology of bleeding and clotting in the cardiac surgery patient: from vascular endothelium to circulatory assist device surface. Circulation (2010) 0.93
Relative purity of thrombin-based hemostatic agents used in surgery. J Am Coll Surg (2003) 0.92
Regenerating titanium ventricular assist device surfaces after gold/palladium coating for scanning electron microscopy. Microsc Res Tech (2010) 0.91
Basic and clinical research in polyomavirus nephropathy. Exp Clin Transplant (2004) 0.90
Surgical salvage of the autogenous arteriovenous fistula (AVF). J Nephrol (2007) 0.89
Management of surgical hemostasis: topical agents. Vascular (2008) 0.88
Improving incident fistula rates: a process of care issue. Am J Kidney Dis (2011) 0.88
Alternative medicine use in dialysis patients: potential for good and bad! Nephron Clin Pract (2006) 0.88
Autogenous arteriovenous fistula options. J Nephrol (2007) 0.88
Bovine thrombin: history, use, and risk in the surgical patient. Vascular (2008) 0.88
Divergent role of donor dendritic cells in rejection versus tolerance of allografts. J Am Soc Nephrol (2009) 0.87
Influence of temporal variation in wall shear stress on intima-media thickening in arteriovenous fistulae. Semin Dial (2012) 0.86
An early study on the mechanisms that allow tissue-engineered vascular grafts to resist intimal hyperplasia. J Cardiovasc Transl Res (2011) 0.86
Use of autologous blood-derived endothelial progenitor cells at point-of-care to protect against implant thrombosis in a large animal model. Biomaterials (2011) 0.85
The balance of thrombosis and hemorrhage in surgery. Hematol Oncol Clin North Am (2007) 0.84
Application of human type I pancreatic elastase (PRT-201) to the venous anastomosis of arteriovenous grafts in patients with chronic kidney disease. J Vasc Access (2014) 0.84
B7h (ICOS-L) maintains tolerance at the fetomaternal interface. Am J Pathol (2013) 0.84
Multicenter evaluation of the bovine mesenteric vein bioprostheses for hemodialysis access in patients with an earlier failed prosthetic graft. J Am Coll Surg (2005) 0.84
"Venopathy" at work: recasting neointimal hyperplasia in a new light. Transl Res (2010) 0.84
Impact of pretransplant anti-HLA antibodies on outcomes in lung transplant candidates. Am J Respir Crit Care Med (2014) 0.84
Salvaging vascular access and treatment of severe limb edema: case reports on the novel use of the hemodialysis reliable outflow vascular access device. Ann Vasc Surg (2011) 0.83
Vascular mapping techniques: advantages and disadvantages. J Nephrol (2007) 0.83
Application of energy-based technologies and topical hemostatic agents in the management of surgical hemostasis. Vascular (2010) 0.83
Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. Transplantation (2010) 0.83
A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in human leukocyte antigen (HLA)-identical live donor renal transplantation. Transplantation (2009) 0.83
Antiphospholipid antibodies after surgical exposure to topical bovine thrombin. J Lab Clin Med (2002) 0.83
African-American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression. Am J Transplant (2005) 0.83
Assessment of vascular contrast and depiction of stenoses in abdominopelvic and lower extremity vasculature: comparison of dual-energy MDCT with digital subtraction angiography. Acad Radiol (2012) 0.82
Comparative analysis of cellular phenotypes within the neointima from vein segments collected prior to vascular access surgery and stenotic arteriovenous dialysis accesses. Semin Dial (2013) 0.81
Body weight alterations under early corticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression. Transplantation (2005) 0.81
Proliferation patterns in a pig model of AV fistula stenosis: can we translate biology into novel therapies? Semin Dial (2014) 0.81
Polyomavirus nephropathy in kidney transplantation. Prog Transplant (2004) 0.81
Immune modulation by Lacto-N-fucopentaose III in experimental autoimmune encephalomyelitis. Clin Immunol (2011) 0.81
Interventional nephrology: from episodic to coordinated vascular access care. J Nephrol (2007) 0.81
Disseminated intravascular coagulation in association with pig-to-primate pulmonary xenotransplantation. Transplantation (2002) 0.81
In vitro functional testing of endothelial progenitor cells that overexpress thrombomodulin. Tissue Eng Part A (2011) 0.81